Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Neoplasms 8Melanoma 6Carcinoma, Non-Small-Cell Lung 5Colorectal Neoplasms 4Carcinoma, Hepatocellular 4Stomach Neoplasms 3Neoplasm Metastasis 3Lymphoma 3Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Nasopharyngeal Carcinoma 2Liver Neoplasms 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Renal Cell 2Advanced Solid Tumors 2Advanced Solid Tumor 2Uterine Cervical Neoplasms 1Solid Tumor 1Skin Neoplasms 1Sarcoma 1Primary Condition: Advanced Tumors 1Neuroendocrine Tumors 1Mouth Neoplasms 1Lung Neoplasms 1Locoregionally Advanced Laryngo-hypopharyngeal Squamous Cell Cancer 1Kidney Neoplasms 1High-Risk Resectable NSCLC 1Esophageal Neoplasms 1Chondrosarcoma 1Carcinoma, Transitional Cell 1

Interventions

Gemcitabine 3Docetaxel 3belinostat 2Fluorouracil 2Bevacizumab 2venetoclax 1toripalimab 1tanespimycin 1ivosidenib 1itacitinib 1durvalumab 1capivasertib 1birinapant 1baricitinib 1Zoledronic Acid 1Thalidomide 1Taxes 1Radiotherapy 1Paclitaxel 1Medicare Part B 1Leucovorin 1Irinotecan 1Immunoglobulin G 1INCB039110 1IFL protocol 1Filgrastim 1Disulfides 1Cisplatin 1Chemotherapy, Adjuvant 1Celecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Chondrosarcoma × toripalimab × Clear all
NCT03474640 2024-11-22

Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies

TopAlliance Biosciences

Phase 1 Completed
184 enrolled 20 charts
GastrointestinalHead & NeckSarcoma

Nasopharyngeal Carcinoma, Chondrosarcoma, Esophageal Neoplasms, Carcinoma, Hepatocellular, Sarcoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡